Serum fructosamine and glycemic status in the presence of the sickle cell mutation.

ABSTRACT:

Aims

The glycated hemoglobin (HbA1c) test can be unreliable in the presence of hemoglobinopathies. The co-existence of type 2 diabetes (T2D) with sickle cell anemia calls for alternative tests. Therefore, we established a reference interval for serum fructosamine and evaluated its utility as a potential glycemic biomarker that is not affected by abnormal hemoglobin.

Methods

The accuracies of serum fructosamine in monitoring and diagnosing T2D were evaluated using the Area under the Receiver Operating Characteristics and other measures in 618 Nigerians with or without sickle cell trait. The estimated diagnostic cut-off for serum fructosamine was then validated in an independent multi-ethnic cohort of 634 West Africans.

Results

Serum fructosamine was similar between ind

SUBMITTER: Doumatey AP 

PROVIDER: S-EPMC8447861 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature